{"id":1131,"date":"2025-08-27T02:02:21","date_gmt":"2025-08-27T02:02:21","guid":{"rendered":"http:\/\/60.204.213.123\/?page_id=1131"},"modified":"2025-08-27T02:02:23","modified_gmt":"2025-08-27T02:02:23","slug":"%e7%bb%93%e8%82%a0%e7%99%8c%e5%b7%b2%e9%aa%8c%e8%af%81%e6%8a%97%e5%8e%9f%e6%b8%85%e5%8d%95-v2","status":"publish","type":"page","link":"https:\/\/www.guixiong.com.cn\/?page_id=1131","title":{"rendered":"\u7ed3\u80a0\u764c\u5df2\u9a8c\u8bc1\u6297\u539f\u6e05\u5355-v2"},"content":{"rendered":"\n

\u672c\u6297\u539f\u6e05\u5355\u5171\u6d89\u53ca145\u79cd\u6297\u539f\u80bd\uff0c\u6765\u81ea21\u7bc72005\u5e74\u81f32024\u5e74\u7684\u7814\u7a76\u6587\u732e\u3002\u8be5\u6e05\u5355\u53ef\u7528\u4e8e\u7ed3\u80a0\u764c\u80bf\u7624\u75ab\u82d7\u7684\u7814\u53d1\u6d4b\u8bd5\uff0c\u4e5f\u53ef\u4ee5\u7528\u4e8e\u7ed3\u80a0\u764cT\u7ec6\u80de\u7597\u6cd5\u7684\u9776\u70b9\u9009\u62e9\u3002\u4e3a\u80fd\u591f\u68c0\u9a8c\u6297\u539f\u80bd\u7684T\u7ec6\u80de\u6d3b\u5316\u7279\u6027\uff0c\u9488\u5bf9\u6bcf\u79cd\u6297\u539f\u80bdHLA\uff0c\u6211\u4eec\u90fd\u5f00\u53d1\u4e86\u56db\u805a\u4f53\uff0c\u4ee5\u7528\u4e8e\u75ab\u82d7\u6d3b\u5316T\u7ec6\u80de\u7684\u6548\u679c\u6d4b\u8bd5\u3002<\/p>\n\n\n\n

\u672c\u6297\u539f\u6e05\u5355\u6765\u6e90\u7684\u6587\u732e\u540d\u79f0<\/h3>\n\n\n\n

<\/p>\n\n\n\n

\u6587\u732e\u9898\u76ee<\/strong><\/td>\u671f\u520a\u540d\u79f0<\/strong><\/td>\u53d1\u8868\u65f6\u95f4<\/strong><\/td>\u6297\u539f\u6570\u91cf<\/strong><\/td><\/tr>
An analogue peptide from the Cancer\/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.<\/strong><\/td>Cancer Immun<\/strong><\/td>2013<\/td>1<\/td><\/tr>
Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening.<\/strong><\/td>Front Immunol<\/strong><\/td>2024<\/td>82<\/td><\/tr>
Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes.<\/strong><\/td>Cell<\/strong><\/td>2018<\/td>26<\/td><\/tr>
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity.<\/strong><\/td>Oncoimmunology<\/strong><\/td>2019<\/td>2<\/td><\/tr>
Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial.<\/strong><\/td>Front Immunol<\/strong><\/td>2022<\/td>3<\/td><\/tr>
Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.<\/strong><\/td>Cell Mol Immunol<\/strong><\/td>2013<\/td>3<\/td><\/tr>
Enhanced anti-colon cancer immune responses with modified eEF2-derived peptides.<\/strong><\/td>Cancer Lett<\/strong><\/td>2015<\/td>3<\/td><\/tr>
First clinical trial of cancer vaccine therapy with artificially synthesized helper\/<\/strong>\u200a<\/strong>killer-hybrid epitope long peptide of MAGE-A4 cancer antigen.<\/strong><\/td>Cancer Sci<\/strong><\/td>2012<\/td>1<\/td><\/tr>
Heat shock protein 90 targets a chaperoned peptide to the static early endosome for efficient cross-presentation by human dendritic cells.<\/strong><\/td>Cancer Sci<\/strong><\/td>2015<\/td>1<\/td><\/tr>
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.<\/strong><\/td>Cancer Immunol Immunother<\/strong><\/td>2014<\/td>10<\/td><\/tr>
Identification and Validation of T-cell Receptors Targeting  Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy.<\/strong><\/td>Clin Cancer Res<\/strong><\/td>2021<\/td>1<\/td><\/tr>
Immunogenicity of somatic mutations in human gastrointestinal cancers.<\/strong><\/td>Science<\/strong><\/td>2015<\/td>9<\/td><\/tr>
Immunotherapeutic benefit of &alpha;-interferon (IFNalpha;) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.<\/strong><\/td>Cancer Sci<\/strong><\/td>2013<\/td>1<\/td><\/tr>
Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses.<\/strong><\/td>Oncoimmunology<\/strong><\/td>2018<\/td>16<\/td><\/tr>
mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer.<\/strong><\/td>J Clin Invest<\/strong><\/td>2020<\/td>20<\/td><\/tr>
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers.<\/strong><\/td>J Clin Invest<\/strong><\/td>2019<\/td>8<\/td><\/tr>
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.<\/strong><\/td>J Immunother Cancer<\/strong><\/td>2019<\/td>2<\/td><\/tr>
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers<\/strong><\/td>Cancer Cell<\/strong><\/td>2023<\/td>3<\/td><\/tr>
Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma.<\/strong><\/td>J Immunother<\/strong><\/td>2005<\/td>1<\/td><\/tr>
Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study.<\/strong><\/td>Clin Cancer Res<\/strong><\/td>2022<\/td>12<\/td><\/tr>
T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes.<\/strong><\/td>Gut<\/strong><\/td>2017<\/td>2<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

\u7ed3\u80a0\u764c\u6297\u539f\u9a8c\u8bc1\u4f7f\u7528\u7684\u65b9\u6cd5\u6e05\u5355<\/h3>\n\n\n\n

\u6bcf\u79cd\u6297\u539f\u5bf9T\u7ec6\u80de\u7684\u6d3b\u5316\u5747\u901a\u8fc7\u4e86\u5b9e\u9a8c\u65b9\u6cd5\u9a8c\u8bc1\uff0c\u5176\u4e2dELISPOT\u662f\u9a8c\u8bc1\u6297\u539f\u6700\u591a\u7684\u65b9\u6cd5\uff0c\u5176\u6b21\u662f\u56db\u805a\u4f53\u8367\u5149\u67d3\u8272\u6cd5\u5224\u65ad\u6297\u539f\u7279\u5f02\u6027T\u7ec6\u80de\u7684\u6d3b\u5316\u6570\u91cf\u3002<\/p>\n\n\n\n

\u68c0\u6d4b\u65b9\u6cd5<\/strong><\/td>\u9274\u5b9a\u7684\u6297\u539f\u6570\u91cf<\/strong><\/td><\/tr>
\u653e\u5c04\u6027\u540c\u4f4d\u7d20 \u2075\u00b9Cr<\/strong>\uff08\u94ec-51\uff09\u6807\u8bb0<\/td>14<\/td><\/tr>
ELISA<\/td>21<\/td><\/tr>
ELISPOT<\/td>190<\/td><\/tr>
IFN-gamma \u6d41\u5f0f\u7ec6\u80de\u67d3\u8272<\/td>6<\/td><\/tr>
\u56db\u805a\u4f53\u67d3\u8272<\/td>42<\/td><\/tr>
surface plasmon resonance (SPR)<\/td>5<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

\u7ed3\u80a0\u764c\u6297\u539f\u7ed3\u5408\u7684HLA\u5206\u5e03<\/h3>\n\n\n\n

\u80bf\u7624\u6297\u539f\u901a\u8fc7\u7ed3\u5408HLA\u5448\u9012\uff0c\u4ee5\u6fc0\u6d3b\u6297\u80bf\u7624\u7684T\u7ec6\u80de\u514d\u75ab\u3002\u5982\u4e0b\u6e05\u5355\u5217\u51fa\u4e86\u7ed3\u80a0\u764c\u6297\u539f\u7ed3\u5408\u7684HLA\u4e9a\u578b\uff0c\u4f7f\u7528\u7ed3\u80a0\u764c\u6297\u539f\u8fdb\u884c\u80bf\u7624\u75ab\u82d7\u5f00\u53d1\u65f6\uff0c\u987b\u53c2\u8003HLA\u5206\u5e03\u7279\u5f81\u3002<\/p>\n\n\n\n

HLA\u7c7b\u578b<\/strong><\/td>\u8868\u4f4d\u6570\u91cf<\/strong><\/td><\/tr>
HLA-A*02:01<\/td>57<\/td><\/tr>
HLA-B*15:01<\/td>27<\/td><\/tr>
HLA-A*02:07<\/td>14<\/td><\/tr>
HLA-A*03:01<\/td>13<\/td><\/tr>
HLA-A*24:02; HLA-C*07:02<\/td>12<\/td><\/tr>
HLA-B*40:01; HLA-C*05:01<\/td>5<\/td><\/tr>
HLA-DQA1*05:01;HLA-DRB1*13:01;HLA-DRB1*03:01;HLA-B*13:02;HLA-C*08:02;HLA-C*06:02<\/td>3<\/td><\/tr>
HLA-B*38:01;HLA-DQB1*02:02;HLA-B*18:01;HLA-C*01:02;HLA-B*27:05;HLA-A*30:02;HLA-DQA1*02:01;HLA-A*32:01;HLA-DQB1*02:01;HLA-B*14:01;HLA-DQB1*06:02;HLA-B*07:02;HLA-DRB1*07:01;HLA-A*23:01;HLA-DRB1*15:01;HLA-DQA1*01:02;HLA-C*03:04<\/td>2<\/td><\/tr>
HLA-DRB1*04:01;HLA-DRA*01:01;HLA-B*08:01;HLA-B*15:11;HLA-A*68:01;HLA-A*01:01;HLA-DQB1*02:05;HLA-B*56:01;HLA-C*07:01;HLA-DQA1*01:03;HLA-DQB1*06:03;HLA-C*04:01<\/td>1<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

\u7ed3\u80a0\u764c\u6297\u539f\u6e05\u5355<\/h3>\n\n\n\n

\u6211\u4eec\u5df2\u5c06\u7ed3\u80a0\u764c\u6297\u539f\u505a\u6210\u4e86\u56db\u805a\u4f53\u590d\u5408\u7269\uff0c\u6297\u539f\u6e05\u5355\u8bf7\u89c1\u94fe\u63a5<\/a>\uff0c\u7528\u6237\u53ef\u76f4\u63a5\u8d2d\u4e70\uff0c\u7528\u4e8e\u68c0\u6d4b\u7ed3\u80a0\u764c\u6297\u539f\u7279\u5f02\u6027T\u7ec6\u80de\u3002<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n

Views: 14<\/p>","protected":false},"excerpt":{"rendered":"

\u672c\u6297\u539f\u6e05\u5355\u5171\u6d89\u53ca145\u79cd\u6297\u539f\u80bd\uff0c\u6765\u81ea21\u7bc72005\u5e74\u81f32024\u5e74\u7684\u7814\u7a76\u6587\u732e\u3002\u8be5\u6e05\u5355\u53ef\u7528\u4e8e\u7ed3\u80a0\u764c\u80bf\u7624\u75ab\u82d7\u7684\u7814\u53d1\u6d4b…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"class_list":["post-1131","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages\/1131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1131"}],"version-history":[{"count":11,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages\/1131\/revisions"}],"predecessor-version":[{"id":1155,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages\/1131\/revisions\/1155"}],"wp:attachment":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}